Neurogranin (Ng) also has been identified as a CSF biomarker associated with AD pathology, and we found that Ng is significantly elevated in a clinical cohort of lvPPA patients that partially overlaps with the cohort presented in the current study (24). Here, NRGN is linked to Alzheimer disease.